UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on St. Jude Medical on Mixed Factors

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on

, but removed the $75.00 price target. In the report, Morgan Stanley noted, “We remain comfortable that St. Jude's top line is poised for acceleration given underlying business strength, CRT-D momentum and CardioMEMs. However, Nanostim's early European failures and MDT's more positive comparative experience did raise concerns at HRS.” St. Jude Medical closed on Thursday at $63.22.